CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00109967 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

71

Enrollment

NIH

Sponsor class

Conditions

Recurrent Mantle Cell Lymphoma

Interventions

BIOLOGICAL: rituximab
DRUG: temsirolimus

Sponsor

National Cancer Institute (NCI)